Prelude Therapeutics Stock Performance
| PRLD Stock | USD 2.80 0.03 1.06% |
Prelude Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of -0.75, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Prelude Therapeutics are expected to decrease at a much lower rate. During the bear market, Prelude Therapeutics is likely to outperform the market. Use Prelude Therapeutics jensen alpha, semi variance, price action indicator, as well as the relationship between the maximum drawdown and daily balance of power , to analyze future returns on Prelude Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Prelude Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain essential indicators, Prelude Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 10.55 | Five Day Return (2.41) | Year To Date Return 3.66 | Ten Year Return (89.20) | All Time Return (89.20) |
1 | Will Prelude Therapeutics Incorporated stock deliver shareholder value - Analyst Upgrade Low Drawdown Trading Strategies - newser.com | 10/24/2025 |
2 | Acquisition by Sandor Victor of 121285 shares of Prelude Therapeutics at 1. subject to Rule 16b-3 | 11/05/2025 |
3 | Prelude Therapeutics Inc Q3 2025 Earnings Call Highlights Strategic Partnerships and ... | 11/12/2025 |
4 | Prelude Therapeutics Incorporated Q3 2025 Earnings Call Transcript | 11/14/2025 |
5 | Is Prelude Therapeutics Incorporated stock supported by strong fundamentals - July 2025 Market Mood Weekly Breakout Stock Alerts - newser.com | 11/17/2025 |
6 | Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo | 11/21/2025 |
7 | VIX Spike How Prelude Therapeutics Incorporated stock compares to industry benchmarks - July 2025 Decliners Growth Focused Stock Pick Reports - moha.gov.vn | 11/28/2025 |
8 | Redhill Biopharma and Prelude Therapeutics Financial Comparison | 12/08/2025 |
9 | Prelude Therapeutics Stock Price Up 2.1 percent - Whats Next - MarketBeat | 12/24/2025 |
10 | Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US2.75m | 12/30/2025 |
| Begin Period Cash Flow | 29.3 M | |
| Total Cashflows From Investing Activities | 90.2 M |
Prelude Therapeutics Relative Risk vs. Return Landscape
If you would invest 126.00 in Prelude Therapeutics on October 10, 2025 and sell it today you would earn a total of 157.00 from holding Prelude Therapeutics or generate 124.6% return on investment over 90 days. Prelude Therapeutics is currently generating 3.0611% in daily expected returns and assumes 22.1842% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Prelude, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Prelude Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prelude Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Prelude Therapeutics, and traders can use it to determine the average amount a Prelude Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.138
| Best Portfolio | Best Equity | |||
| Good Returns | PRLD | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Prelude Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prelude Therapeutics by adding it to a well-diversified portfolio.
Prelude Therapeutics Fundamentals Growth
Prelude Stock prices reflect investors' perceptions of the future prospects and financial health of Prelude Therapeutics, and Prelude Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prelude Stock performance.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (3.14) % | ||||
| Current Valuation | 116.29 M | ||||
| Shares Outstanding | 50.02 M | ||||
| Price To Book | 2.62 X | ||||
| Price To Sales | 15.33 X | ||||
| Revenue | 7 M | ||||
| Gross Profit | 10.5 M | ||||
| EBITDA | (137.94 M) | ||||
| Net Income | (127.17 M) | ||||
| Cash And Equivalents | 246.3 M | ||||
| Cash Per Share | 5.19 X | ||||
| Total Debt | 18.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.73 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | (102.89 M) | ||||
| Earnings Per Share | (1.47) X | ||||
| Market Capitalization | 160.94 M | ||||
| Total Asset | 175.51 M | ||||
| Retained Earnings | (583.56 M) | ||||
| Working Capital | 110.25 M | ||||
About Prelude Therapeutics Performance
By analyzing Prelude Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Prelude Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prelude Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prelude Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (1.11) | (1.06) |
Things to note about Prelude Therapeutics performance evaluation
Checking the ongoing alerts about Prelude Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prelude Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Prelude Therapeutics is way too risky over 90 days horizon | |
| Prelude Therapeutics appears to be risky and price may revert if volatility continues | |
| Prelude Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 10.5 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Prelude Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from simplywall.st: Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US2.75m |
- Analyzing Prelude Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prelude Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Prelude Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Prelude Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prelude Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Prelude Therapeutics' stock. These opinions can provide insight into Prelude Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |